Gabriele Domenico Gallina

Dr. Gabriele Domenico Gallina

Immunology Rheumatology and Rare Disease, IRCCS Ospedale San Raffaele, Milan, Lombardy, Italy
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
MRMarco Ripa
Marco Ripa
LGLaura Galli
Laura Galli
APAndrea Poli
Andrea Poli
COChiara Oltolini
Chiara Oltolini
VSVincenzo Spagnuolo
Vincenzo Spagnuolo
CVConcetta Vinci
Concetta Vinci

1 October 2021 in Metabolism
Verified
Journal Article
Closed access
SCStefania L. Calvisi
Stefania L. Calvisi
GRGiuseppe A. Ramirez
Giuseppe A. Ramirez
MSMarina Scavini
Marina Scavini
VPValentina Da Prat
Valentina Da Prat
GLGiuseppe Di Lucca
Giuseppe Di Lucca
LPLorenzo Piemonti
Lorenzo Piemonti

1 July 2024 in The Journal of Rheumatology
Verified
Journal Article
Closed access
PDF file
CTChiara Tani
Chiara Tani
CCChiara Cardelli
Chiara Cardelli
MZMargherita Zen
Margherita Zen
LMLuca Moroni
Luca Moroni
PMPiga Matteo
Piga Matteo
MMMarta Mosca
Marta Mosca
Objective: To report real-world experience on the use of anifrolumab (ANI) in refractory systemic lupus erythematosus (SLE). Methods: The present study is a multicenter, retrospective study involving 9 Italian SLE referral centers participating in a compassionate use program for the use of ANI in adult patients with active SLE in whom all the available treatment choices failed, were not tolerated, or were contraindicated. At baseline and 1, 3, 6, 9, and 12 months of treatment, overall and organ-specific disease activity, flares, daily glucocorticoid (GC) dose, and adverse events were recorded. Results: A total of 26 patients were enrolled. At 4 weeks after starting ANI, a significant decrease in the Systemic Lupus Erythematosus Disease Activity Index 2000 (P = 0.01), Systemic Lupus Erythematosus–Disease Activity Score (P = 0.01), and physician global assessment (P = 0.001) was recorded, and the same trend was maintained over time. A significant reduction in Cutaneous Lupus Erythematosus Disease Area and Severity Index-activity (P < 0.001) and in tender (P = 0.03) and swollen (P = 0.02) joint counts was also recorded. At 3 months of follow-up, 33% of patients already achieved a remission state, whereas 46% were in Lupus Low Disease Activity State (LLDAS); at 6 months, 50% were in remission and 80% were in LLDAS. A significant reduction in the mean GC daily dose was observed, starting from week 4 (P = 0.04). A total of 4 disease flares according to the Safety of Estrogens in Lupus Erythematosus National Assessment–Systemic Lupus Erythematosus Disease Activity Index were recorded (3 mild-moderate and 1 severe). Overall, 4/20 patients with at least 24 weeks of follow-up (20%) were considered nonresponders. Conclusion: This study provides real-world experience on the use of ANI in patients with refractory SLE, confirming its rapid effectiveness and an overall acceptable safety profile.

6 May 2023 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
LMLuca Moroni
Luca Moroni
LGLaura Giudice
Laura Giudice
Marco LanzillottaMarco Lanzillotta
Marco Lanzillotta
ACAdriana Cariddi
Adriana Cariddi
GRGiuseppe A. Ramirez
Giuseppe A. Ramirez
LDLorenzo Dagna
Lorenzo Dagna

12 April 2025 in Rheumatology
Verified
Journal Article
Closed access
LMLuca Moroni
Luca Moroni
VBVeronica Batani
Veronica Batani
GGGabriele Domenico Gallina
Gabriele Domenico Gallina
GBGiovanni Benanti
Giovanni Benanti
MCMaria Cilona
Maria Cilona
LDLorenzo Dagna
Lorenzo Dagna
Objectives: To evaluate the efficacy and safety of a step-down treatment approach using mepolizumab for eosinophilic granulomatosis with polyangiitis (EGPA) in a real-life single-centre cohort. The study aimed to assess outcomes following a transition from high-dose (300 mg/4 weeks) to low-dose (100 mg/4 weeks) mepolizumab after achieving remission. Methods: This retrospective study included EGPA patients treated with mepolizumab between April 2014 and December 2024. Patients receiving step-down therapy were in remission, defined by a Birmingham Vasculitis Activity Score (BVAS) of 0, Asthma Control Test (ACT) >20 and steroid-free for at least one year. Disease activity, eosinophil counts and systemic glucocorticoids (GC) use were tracked in medical charts. Results: Among 45 patients initially treated with 300 mg/4 weeks, 12 (27%) switched to 100 mg/4 weeks after a median of 26.5 months. Over a median follow-up of 27.5 months post-step-down, 50% maintained complete remission without GC therapy. In 50% of patients sinonasal symptoms recurred and were treated with either increased mepolizumab dose or optimization of local therapy. No asthma or vasculitis exacerbations occurred. Conclusion: Our preliminary data show that step-down therapy with mepolizumab to 100 mg/4 weeks was effective in maintaining systemic remission and reducing GC use in EGPA patients. However, recurrence of sinonasal symptoms suggests the need for an individualized management. Larger studies are warranted to confirm these findings and optimize dosing strategies for long-term care.

14 December 2022 in Lupus
Verified
Journal Article
Open access
LMLuca Moroni
Luca Moroni
MMMartina Mazzetti
Martina Mazzetti
GRGiuseppe A. Ramirez
Giuseppe A. Ramirez
SZSimone Zuffada
Simone Zuffada
ACAnna Ciancio
Anna Ciancio
LDLorenzo Dagna
Lorenzo Dagna
Objectives: Neuropsychiatric symptoms develop in up to 20% of the patients with Systemic Lupus Erythematosus (SLE). Growing evidence is accruing on the association of SLE with Post-traumatic Stress Disorder (PTSD), but little is known about its contribution on patient-reported outcomes. This study focuses on PTSD prevalence in our SLE cohort and on its impact on quality of life. Methods: Trauma and Loss Spectrum – Self Reported (TALS-SR) and Lupus Quality of Life (Lupus QoL) questionnaires were administered via web to the patients with SLE in our cohort, along with questions on demographical and disease-related aspects. Results: Among 99 patients who completed the questionnaire, fatigue prevalence was 75% and 31% scored TALS-SR test consistently with PTSD. Patients with PTSD achieved lower scores compared to those without PTSD in three Lupus QoL domains: planning (83.3 vs. 100, p = .035), body image (85.0 vs. 95.0, p = .031) and fatigue (66.7 vs. 91.7, p = .001). An inverse correlation was found between TALS-SR domains and Lupus QoL scores, particularly regarding fatigue with reaction to losses or upsetting events (ρ -0.458, p < .001). Conclusions: PTSD is possibly far more frequent in patients with SLE than in general population and exerts a detrimental influence on quality of life.